“With molecular engineering at our core, we aim to move beyond discovery towards scalable biological design that can precisely address previously intractable genetic maladies.” “We are building a future where treating the underlying causes of disease will be achieved by best-in-class, custom engineered technologies,” said Benjamin Oakes, CEO and co-founder of Scribe Therapeutics. The company’s unmatched expertise and track record in CRISPR and protein engineering have allowed it to hone its fully integrated and proprietary CRISPR technologies for efficacy, specificity, and deliverability. “Scribe’s engineering-first philosophy has resulted in a uniquely flexible platform for imagining and creating a new era of CRISPR-based therapies to elevate the standard of care for thousands of patients,” said Jennifer Doudna, co-inventor of CRISPR technology, Nobel Laureate, and co-founder of Scribe Therapeutics.įounded to address the issues of safety, delivery, poor editing outcomes, and an uncertain intellectual property landscape that limit current CRISPR technologies, Scribe’s evergreen engineering platform creates custom molecules specifically designed for therapeutic use within the human body.
The capital will be used to further develop Scribe’s suite of custom gene editing and delivery technologies, as well as to advance a pipeline of therapeutics for neurodegeneration and additional diseases with high unmet need. Gordon, managing partner at OrbiMed Advisors, will join Scribe’s Board of Directors. As part of the financing, Behzad Aghazadeh, managing partner at Avoro Ventures and Avoro Capital Advisors, and Carl L. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment firm also joined the syndicate. Perceptive Advisors, funds and accounts advised by T. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz.
SCRIBE THERAPEUTICS SERIES
“With molecular engineering at our core, we aim to move beyond discovery towards scalable biological design that can precisely address previously intractable genetic maladies,” he added.Molecular engineering company’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of diseaseĪLAMEDA, Calif.–( BUSINESS WIRE)–Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. “We are building a future where treating the underlying causes of disease will be achieved by best-in-class, custom engineered technologies,” said Benjamin Oakes, chief executive officer and co-founder of Scribe Therapeutics. Scribe is also exploring additional therapeutic targets, as well as new partnership opportunities, the company said in a statement. The company is already conducting a $400m research collaboration with Biogen to develop CRISPR-based therapies for Amyotrophic Lateral Sclerosis (ALS). It is also looking to engineer additional technologies as part of its expanding platform while developing its pipeline to target areas of unmet need.
Scribe has already engineered CRISPR enzymes found in nature into millions of novel variants, which it says have ideal therapeutic attributes to enable ‘highly effective and specific in vivo applications’. “Scribe’s engineering-first philosophy has resulted in a uniquely flexible platform for imagining and creating a new era of CRISPR-based therapies to elevate the standard of care for thousands of patients,” said Jennifer Doudna, co-inventor of CRISPR technology, Nobel Laureate and co-founder of Scribe Therapeutics. Scribe’s technology platform can create custom CRISPR molecules that are specifically designed for therapeutic use within the body, overcoming the limitation of using existing enzymes that may lead to ‘poor editing outcomes’. This technology evolved from the natural defence mechanisms of bacteria and archaea, which use RNA and Cas proteins to target and attack viruses and other foreign bodies. The company’s platform is based on CRISPR technology (also known as CRISPR-Cas9) – CRISPRs are specialised stretches of DNA that can be cut by Cas9 enzymes. Scribe was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology and co-recipient of the 2020 Nobel Prize in Chemistry. Scribe Therapeutics has completed an oversubscribed $100m Series B financing round to advance the development of its CRISPR platform and pipeline.
0 kommentar(er)
